Frequently asked questions

Answers to some common questions about AQNEURSA

These answers are not intended to replace a discussion about AQNEURSA with a healthcare provider.

In the clinical trial, people with NPC who were given AQNEURSA were evaluated after 6 weeks, and again after 12 weeks, of treatment. 
The most common side effects of AQNEURSA include abdominal pain (pain in the belly or stomach area), dysphagia (trouble swallowing), upper respiratory tract infections (infections of the nose, mouth, or throat), and vomiting. Speak with your healthcare provider if you or someone you care for experiences these side effects and if these side effects persist or worsen.
AQNEURSA is taken by mouth or via a gastrostomy tube (G-tube) 2 to 3  times per day. The drug should be taken exactly as prescribed. AQNEURSA can be taken with or without food.
If a dose of AQNEURSA is missed, skip the missed dose and take the next dose at the scheduled time. Do not take 2 doses at the same time to make up for the missed dose.

“There were significant improvements in our daily life. Regular activities are possible more often.”

– Parents of a child treated with AQNEURSA in the clinical trial. This is an individual's experience and cannot be considered to reflect the entire population.

Sign up to get more information

Stay informed
Important Safety Information
Do not take AQNEURSA if you:
  • have not had a negative pregnancy test. If you become pregnant while taking AQNEURSA, inform your doctor immediately to discuss potential risks and alternative treatments
Before taking AQNEURSA, discuss with your doctor if you:
  • are pregnant or planning to become pregnant. Based on findings from animal reproduction studies, AQNEURSA may cause harm to your unborn baby when administered during pregnancy. If you become pregnant while taking AQNEURSA, inform your doctor immediately to discuss potential risks and alternative treatments.
  • require the need for effective contraception during treatment with AQNEURSA and for 7 days after stopping treatment to avoid pregnancy.
  • are breastfeeding or plan to breastfeed. It is not known if AQNEURSA or its metabolites pass into human or animal milk or effects on breastmilk production
  • are taking P-gp substrate. Your doctor will monitor you for related adverse reactions
  • have any other medical conditions
  • are taking any medications and supplements, including N-acetyl-DL-leucine or N-acetyl-D-leucine, as some of these may impact the effectiveness of AQNEURSA
Back to top

IMPORTANT SAFETY INFORMATION

Do not take AQNEURSA if you:

  • have not had a negative pregnancy test. If you become pregnant while taking AQNEURSA, inform your doctor immediately to discuss potential risks and alternative treatments

Before taking AQNEURSA, discuss with your doctor if you:

  • are pregnant or planning to become pregnant. Based on findings from animal reproduction studies, AQNEURSA may cause harm to your unborn baby when administered during pregnancy. If you become pregnant while taking AQNEURSA, inform your doctor immediately to discuss potential risks and alternative treatments.
  • require the need for effective contraception during treatment with AQNEURSA and for 7 days after stopping treatment to avoid pregnancy.
  • are breastfeeding or plan to breastfeed. It is not known if AQNEURSA or its metabolites pass into human or animal milk or effects on breastmilk production
  • are taking P-gp substrate. Your doctor will monitor you for related adverse reactions
  • have any other medical conditions
  • are taking any medications and supplements, including N-acetyl-DL-leucine or N-acetyl-D-leucine, as some of these may impact the effectiveness of AQNEURSA

Indication

AQNEURSA (levacetylleucine) is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.